These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 27842666)

  • 1. Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography.
    Schabel C; Horger M; Kum S; Weisel K; Fritz J; Ioanoviciu SD; Bier G
    Eur J Radiol; 2016 Dec; 85(12):2195-2199. PubMed ID: 27842666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-Body Low-Dose CT in Multiple Myeloma: Diagnostic Value of Appendicular Medullary Patterns of Attenuation.
    Koutoulidis V; Terpos E; Klapa I; Cheliotis G; Ntanasis-Stathopoulos I; Boultadaki A; Gavriatopoulou M; Kastritis E; Dimopoulos MA; Moulopoulos LA
    AJR Am J Roentgenol; 2021 Mar; 216(3):742-751. PubMed ID: 33439048
    [No Abstract]   [Full Text] [Related]  

  • 3. A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography.
    Takasu M; Tani C; Kaichi Y; Sakoda Y; Kiguchi M; Date S; Kuroda Y; Sakai A; Awai K
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):485-92. PubMed ID: 25190250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can whole-body low-dose multidetector CT exclude the presence of myeloma bone disease in patients with monoclonal gammopathy of undetermined significance (MGUS)?
    Spira D; Weisel K; Brodoefel H; Schulze M; Kaufmann S; Horger M
    Acad Radiol; 2012 Jan; 19(1):89-94. PubMed ID: 22142681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved Follow-Up and Response Monitoring of Thoracic Cage Involvement in Multiple Myeloma Using a Novel CT Postprocessing Software: The Lessons We Learned.
    Bier G; Mustafa DF; Kloth C; Weisel K; Ditt H; Nikolaou K; Horger M
    AJR Am J Roentgenol; 2016 Jan; 206(1):57-63. PubMed ID: 26700335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma.
    Horger M; Kanz L; Denecke B; Vonthein R; Pereira P; Claussen CD; Driessen C
    Cancer; 2007 Apr; 109(8):1617-26. PubMed ID: 17330855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing bone sclerosis during bortezomib therapy in multiple myeloma patients: results of a reduced-dose whole-body MDCT study.
    Schulze M; Weisel K; Grandjean C; Oehrlein K; Zago M; Spira D; Horger M
    AJR Am J Roentgenol; 2014 Jan; 202(1):170-9. PubMed ID: 24370141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffusion-weighted whole-body MRI for evaluation of early response in multiple myeloma.
    Lacognata C; Crimì F; Guolo A; Varin C; De March E; Vio S; Ponzoni A; Barilà G; Lico A; Branca A; De Biasi E; Gherlinzoni F; Scapin V; Bissoli E; Berno T; Zambello R
    Clin Radiol; 2017 Oct; 72(10):850-857. PubMed ID: 28587715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of qualitative and quantitative CT and MRI parameters for monitoring of longitudinal spine involvement in patients with multiple myeloma.
    Horger M; Fritz J; Thaiss WM; Ditt H; Weisel K; Haap M; Kloth C
    Skeletal Radiol; 2018 Mar; 47(3):351-361. PubMed ID: 29222688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-body diffusion-weighted MRI for evaluation of response in multiple myeloma patients following bortezomib-based therapy: A large single-center cohort study.
    Zhang Y; Xiong X; Fu Z; Dai H; Yao F; Liu D; Deng S; Hu C
    Eur J Radiol; 2019 Nov; 120():108695. PubMed ID: 31589995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-body low-dose CT recognizes two distinct patterns of lytic lesions in multiple myeloma patients with different disease metabolism at PET/MRI.
    Zambello R; Crimì F; Lico A; Barilà G; Branca A; Guolo A; Varin C; Vezzaro R; Checuz L; Scapin V; Berno T; Pizzi M; Ponzoni A; De Biasi E; Vio S; Semenzato G; Zucchetta P; Lacognata C
    Ann Hematol; 2019 Mar; 98(3):679-689. PubMed ID: 30539276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-body diffusion-weighted MRI with apparent diffusion coefficient mapping for early response monitoring in multiple myeloma: preliminary results.
    Horger M; Weisel K; Horger W; Mroue A; Fenchel M; Lichy M
    AJR Am J Roentgenol; 2011 Jun; 196(6):W790-5. PubMed ID: 21606271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
    Mileshkin L; Honemann D; Gambell P; Trivett M; Hayakawa Y; Smyth M; Beshay V; Ritchie D; Simmons P; Milner AD; Zeldis JB; Prince HM
    Haematologica; 2007 Aug; 92(8):1075-82. PubMed ID: 17640854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CT imaging of bone and bone marrow infiltration in malignant melanoma--Challenges and limitations for clinical staging in comparison to 18FDG-PET/CT.
    Bier G; Hoffmann V; Kloth C; Othman AE; Eigentler T; Garbe C; La Fougère C; Pfannenberg C; Nikolaou K; Klumpp B
    Eur J Radiol; 2016 Apr; 85(4):732-8. PubMed ID: 26971416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of whole-body low-dose computed tomography (WBLDCT) in bone lesions detection in patients with multiple myeloma (MM).
    Ippolito D; Besostri V; Bonaffini PA; Rossini F; Di Lelio A; Sironi S
    Eur J Radiol; 2013 Dec; 82(12):2322-7. PubMed ID: 24074647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Automated "Bone Subtraction" Image Analysis Software Package for Improved and Faster CT Monitoring of Longitudinal Spine Involvement in Patients with Multiple Myeloma.
    Horger M; Ditt H; Liao S; Weisel K; Fritz J; Thaiss WM; Kaufmann S; Nikolaou K; Kloth C
    Acad Radiol; 2017 May; 24(5):623-632. PubMed ID: 28256439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters.
    Horger M; Pereira P; Claussen CD; Kanz L; Vonthein R; Denecke B; Driessen C
    Br J Radiol; 2008 May; 81(965):386-96. PubMed ID: 18440943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone formation following lenalidomide-dexamethasone combination therapy in cases of multiple myeloma refractory to high-dose chemotherapy with bortezomib and autologous peripheral blood stem cell transplantation: report of a case and review of the literature.
    Sekiguchi Y; Ichikawa K; Wakabayashi M; Sugimoto K; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
    Int J Clin Exp Pathol; 2015; 8(8):9609-19. PubMed ID: 26464727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bone disease in multiple myeloma. A study of 237 cases].
    Scutellari PN; Orzincolo C; Bagni B; Feggi L; Franceschini F; Spanedda R
    Radiol Med; 1992 May; 83(5):542-60. PubMed ID: 1631329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of dynamic contrast-enhanced sonography for characterization and monitoring of extramedullary myeloma: comparison with serologic data.
    Pintoffl JP; Weisel K; Schulze M; Maksimovic O; Claussen CD; Kramer U; Horger M
    J Ultrasound Med; 2013 Oct; 32(10):1777-88. PubMed ID: 24065259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.